Form 4: Terns Pharmaceuticals CMO Sells Shares for Tax Obligations

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 853 shares of common stock to cover tax liabilities associated with a restricted stock unit award vesting.

Summary

• Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals, Inc. (TERN), reported a sale of 853 shares of common stock.
• The transaction occurred on July 1, 2025, and was executed at a weighted average sale price of $4.2671 per share.
• The sale price ranged from $4.215 to $4.32 per share.
• This sale was non-discretionary, specifically undertaken to satisfy tax obligations arising from the vesting of a previously granted restricted stock unit (RSU) award.
• Following this transaction, Emil Kuriakose beneficially owns 52,464 shares of Terns Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale to cover tax obligations from a vested RSU award, not indicative of management's view on the company's future prospects.

Future Outlook

NA

Management Comments

• The sale of shares represents common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person.
• Such sales do not represent a discretionary trade by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale to cover tax obligations from a vested restricted stock unit award, not a reflection of a change in company outlook or strategy.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, SEC Form 4, Insider Transaction, Emil Kuriakose, Chief Medical Officer, Restricted Stock Unit, Tax Obligation, Stock Sale